The management of non-small cell lung cancer (NSCLC) is evolving significantly, as recent presentations reveal a shift toward the incorporation of protein-based biomarkers and computational techniques....
The European Commission (EC) has granted approval for tislelizumab (Tevimbra) as a combination treatment for adults with resectable non-small cell lung cancer (NSCLC) at high risk...
